HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.

Competing Interests: Competing interests: AWM is supported National Institute for Health and Care Research (NIHR) and Medical Research Council (MRC). AWM has acted as consultant for Roche/Chugai, Vifor and AstraZeneca. AWM is member of speakers’ bureaus for Roche/Chugai. AWM is on Data Safety Monitoring Board for GSK and Regeneron/Sanofi. AWM is on the board for MRC and Vasculitis UK. KH has received grant/research support from Pfizer, Bristol Myers Squibb (BMS). KH has received honoraria for speaking at educational meeting by Abbvie. AB is supported by the NIHR Manchester Biomedical Research Centre. AB has received grant/research support from Pfizer, BMS, Scipher Medicine and Galapagos (paid to host institution). AB is member of speakers’ bureaus for Galapagos (paid to host institution). DP has received grant/research support from BMS, Versus Arthritis and European Commission.